Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06626022 · ClinicalTrials.gov registry record · Phase 3
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
A Phase 3 study of Prostate Cancer Screening, sponsored by University of Alberta.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,284
- Enrollment target
- 5
- Study locations
NCT06626022: Recruiting Phase 3 study of Prostate Cancer Screening, sponsored by University of Alberta.
NCT06626022 is a Phase 3 study of Prostate Cancer Screening that is actively recruiting participants, run by University of Alberta. The registered enrollment target is 1,284 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06626022, a Phase 3 study of Prostate Cancer Screening, is actively recruiting participants, sponsored by University of Alberta.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,284 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to compare whether the FDA and Health Canada approved microUS is as effective as the currently used option (MRI) for imaging the prostate gland. Participants will be randomized into two groups to compare the imaging results of the current standard of care MRI and the new microUS. The study is looking to identify the most effective imaging modality to help guide whether you progress to have a prostate biopsy.
Primary Outcome
The primary objective of this trial is to determine if a screening pathway using microUS is non-inferior to a pathway using MRI for the detection of clinically significant prostate cancer, defined as Gleason Grade Group 2 or more.
Conditions Studied
Interventions
- DEVICE MRI
- DEVICE ExactVu
Study Locations (5)
California
- University of California, Los Angeles (UCLA) - Los Angeles
Alberta
- University of Alberta - Edmonton
British Columbia
- University of British Columbia - Vancouver
Quebec
- CIUSSS du Nord-de-l'Île-de-Montréal - Montréal
Other
- Urologia Clinica Bilbao - Bilbao
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,284 participants |
| Start Date | 2025-05-08 |
| Est. Completion | 2029-11-30 |
| Phase | Phase 3 |
What NCT06626022 shows while recruiting
NCT06626022 is an interventional study that assigns participants to a tested intervention. Its 1,284 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% higher).
The record links to 1 condition, with Prostate Cancer Screening appearing as the primary indexed condition, and to 2 interventions - of which MRI is the first listed.
NCT06626022 lists 5 locations in 5 states (California, Alberta, British Columbia).
Frequently Asked Questions
What is clinical trial NCT06626022 about?
NCT06626022 is a clinical study titled "Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.". The purpose of this study is to compare whether the FDA and Health Canada approved microUS is as effective as the currently used option (MRI) for imaging the prostate gland. Participants will be randomized into two groups to compare the imaging results of the current standard of care MRI and the new...
What is the current status of trial NCT06626022?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,284 participants. The study started on 2025-05-08. Estimated completion is 2029-11-30.
What conditions does trial NCT06626022 study?
This clinical trial studies the following conditions: Prostate Cancer Screening.
What interventions are being tested in trial NCT06626022?
The interventions under investigation include: MRI (DEVICE), ExactVu (DEVICE).
Who is sponsoring clinical trial NCT06626022?
This trial is sponsored by University of Alberta, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06626022 being conducted?
This trial has 5 study locations across California, Alberta, British Columbia, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer Screening
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06626022's enrollment target sits among peer trials
1,284 197th of 2000 higher than 1,804 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03970447 · 1,280 participants · Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- NCT06468228 · 1,280 participants · Phase 3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- NCT07207811 · 1,280 participants · Phase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
- NCT05595642 · 1,290 participants · Phase 3
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI